RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Rein Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.55−0.04 (-6.49%)
Close on Oct 19, 2026
- Market cap
- $37.03M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Share price
−$0.6680 (−54.75%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Rein Therapeutics, Inc. reported revenue of $0 for the twelve months to Jun 30, 2026.
Revenue
$0
TTM Q2 2026
Operating income
-$49.46M
TTM Q2 2026
EPS, diluted
-$1.59
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $37.03M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.67
- Dividend yield
- 0.00%
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$49.76M
- EPS, diluted
- -$1.59
- Book value per share
- $0.82
- Diluted shares
- 67M
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
$0
Operating income
-$49.46M
Net income
-$49.76M
EPS, diluted
-$1.59
Free cash flow
–
Reported periodTrailing twelve months